Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9

Table 1 Clinical characteristics

	Controls, n	PaC, n
All	99	84
Male	46	45
Female	53	39
Caucasian	75	77
African American	23	6
Other	1	1
Age (yr), median	45 (19-85)	64 (41-96)
TNM Stage
I/II		11
III/IV		23
Stage unknown		50
Surgery
Sample collected prior to surgery		38
Sample collected after surgery		23
NA		23
Chemo
Sample collected prior to chemo		6
Sample collected after chemo		17
Sample collected during chemo		56
NA		5
Radiation
Sample collected prior radiation		47
Sample collected after radiation		11
Sample collected during radiation		3
NA		23

NA: Not available.

Table 2 t-test results of ethnicity and treatment status on PC-594 levels

Comparison	P value
African American (23) vs Caucasian (75)	0.18
Surgery pre (38) vs post (23)	0.20
Chemo pre (6) vs post (17)	0.40
Chemo post (17) vs active (56)	0.06
Radiation pre (47) vs post (11)	0.10

Table 3 Interaction between CA19-9 and PC-594 n (%)

CA19-9 (U/mL)	PC-594 (μmol/L)	PaC	Control
Abnormal		54 (64)	5 (5)
	Abnormal	72 (86)	9 (9)
Abnormal	Abnormal	48 (57)	0 (0)
Abnormal	Normal	6 (7)	5 (5)
Normal	Abnormal	24 (29)	9 (9)
Normal	Normal	6 (7)	85 (86)

Abnormal CA19-9: Greater than 35 U/mL. PaC: Pancreatic cancer.